Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells.
暂无分享,去创建一个
A. Nicosia | B. Marinari | L. Tuosto | P. Del Porto | C. Scottà | M. Carbonari | E. Piccolella | L. Frasca
[1] Miles P. Davenport,et al. HIV-1 Variation Diminishes CD4 T Lymphocyte Recognition , 1998, The Journal of experimental medicine.
[2] S. Tonegawa,et al. CD4+ T Cells Prevent Spontaneous Experimental Autoimmune Encephalomyelitis in Anti–Myelin Basic Protein T Cell Receptor Transgenic Mice , 1998, The Journal of experimental medicine.
[3] Y. Liaw,et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. , 1998, Gastroenterology.
[4] D. Speiser,et al. Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism , 1998, European journal of immunology.
[5] Colin R. F. Monks,et al. Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.
[6] R. Ahmed,et al. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. , 1998, Current opinion in immunology.
[7] Anna Tramontano,et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross‐reacting with a large number of viral variants , 1998, The EMBO journal.
[8] P. Klenerman,et al. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[10] D. Kwiatkowski,et al. Association of malaria parasite population structure, HLA, and immunological antagonism. , 1998, Science.
[11] H. Thomas,et al. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients , 1998, Hepatology.
[12] A. Lanzavecchia,et al. A T cell receptor (TCR) antagonist competitively inhibits serial TCR triggering by low‐affinity ligands, but does not affect triggering by high‐affinity anti‐CD3 antibodies , 1997, European journal of immunology.
[13] A. Sette,et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. , 1997, The Journal of clinical investigation.
[14] R. Germain,et al. T-cell signaling: The importance of receptor clustering , 1997, Current Biology.
[15] R. Phillips,et al. Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides , 1997, European journal of immunology.
[16] R. Germain,et al. Single Cell Analysis Reveals Regulated Hierarchical T Cell Antigen Receptor Signaling Thresholds and Intraclonal Heterogeneity for Individual Cytokine Responses of CD4+ T Cells , 1997, The Journal of experimental medicine.
[17] A. Sette,et al. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] H. Yagita,et al. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope , 1997, European journal of immunology.
[19] Mark M. Davis,et al. Ligand-specific oligomerization of T-cell receptor molecules , 1997, Nature.
[20] O. Weiland,et al. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. , 1997, The Journal of infectious diseases.
[21] T. Preckel,et al. Altered Hapten Ligands Antagonize Trinitrophenyl-specific Cytotoxic T Cells and Block Internalization of Hapten-specific Receptors , 1997, The Journal of experimental medicine.
[22] C. Janeway,et al. Peptide antagonists inhibit proliferation and the production of IL-4 and/or IFN-gamma in T helper 1, T helper 2, and T helper 0 clones bearing the same TCR. , 1997, Journal of immunology.
[23] M. Uhlén,et al. Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. , 1997, The Journal of infectious diseases.
[24] S. Kent,et al. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. , 1997, Journal of immunology.
[25] N. Suciu-Foca,et al. Allopeptide-specific T cell reactivity altered by peptide analogs. , 1997, Journal of immunology.
[26] R. Purcell,et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. , 1996, Virology.
[27] M. Mondelli. Is there a role for immune responses in the pathogenesis of hepatitis C? , 1996, Journal of hepatology.
[28] M. Massari,et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. , 1996, The Journal of clinical investigation.
[29] Y. Chien,et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. , 1996, Immunity.
[30] C. Janeway,et al. The specificity and orientation of a TCR to its peptide-MHC class II ligands. , 1996, Immunity.
[31] N. Enomoto,et al. Hepatitis C virus quasispecies populations during chronic hepatitis C infection. , 1995, Trends in microbiology.
[32] T. Santantonio,et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection , 1995, The Lancet.
[33] J. Rothbard,et al. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. , 1995, Immunity.
[34] A. Lanzavecchia,et al. Serial triggering of many T-cell receptors by a few peptideMHC complexes , 1995, Nature.
[35] R. Karr,et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association , 1995, The Journal of experimental medicine.
[36] E. Schreier,et al. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. , 1995, Virology.
[37] A. Hughes,et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Strominger,et al. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein , 1995, Cell.
[39] G. Riethmüller,et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection , 1995, Hepatology.
[40] L. van Doorn,et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses , 1995, Journal of virology.
[41] L. Samelson,et al. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists , 1995, Science.
[42] Paul M. Allen,et al. Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy , 1994, Cell.
[43] N. Enomoto,et al. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. , 1994, Virology.
[44] A. Sette,et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. , 1994, Journal of immunology.
[45] L. Tuosto,et al. Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta T cell clone. , 1994, Journal of immunology.
[46] M. Shapiro,et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] A. Sette,et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.
[48] Sarah Rowland-Jones,et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.
[49] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[50] C. Ferrari,et al. T‐cell response to structural and nonstructural hepatitis C virus antigens in persistent and self‐limited hepatitis C virus infections , 1994, Hepatology.
[51] F. Sinigaglia,et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides , 1993, Cell.
[52] H. Grey,et al. Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Weiner,et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.
[54] S. Roman-Roman,et al. An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.
[55] H. Grey,et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor , 1992, Cell.
[56] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[57] E. Piccolella,et al. CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells. , 1998, Critical reviews in immunology.
[58] A. Lanzavecchia,et al. The duration of antigenic stimulation determines the fate of naive and effector T cells. , 1998, Immunity.
[59] R. Germain,et al. Single Cell Analysis Reveals Regulated Hierarchical T Cell Antigen Receptor Signaling Thresholds and Intraclonal Heterogeneity for Individual Cytokine Responses of CD 4 1 T Cells , 1997 .
[60] N. Suciu-Foca,et al. New approaches to specific immunomodulation in transplantation. , 1996, International reviews of immunology.
[61] P. Allen,et al. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. , 1996, Annual review of immunology.
[62] M. Bevan,et al. T cell receptor antagonists and partial agonists. , 1995, Immunity.